{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:53:48Z","timestamp":1793912028454,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.radonc.2024.110240","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:42:50Z","timestamp":1711154570000},"page":"110240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-2439","authenticated-orcid":false,"given":"D.","family":"Franceschini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Comito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Ilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Spoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0165-7931","authenticated-orcid":false,"given":"P.","family":"Mancosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110240_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0010","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.3390\/cancers15153902","article-title":"A bibliometric analysis of the Oligometastatic state over the last two decades: a shifting Paradigm for oncology? an AIRO Oligometastatic study group","volume":"15","author":"Marvaso","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110240_b0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0020","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0025","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0030","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdt537","article-title":"Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival","volume":"25","author":"de Vin","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0040","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110240_b0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for longterm survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2024.110240_b0050","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.21037\/tcr.2020.01.04","article-title":"Diagnosis of oligometastasis","volume":"9","author":"Terao","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.radonc.2024.110240_b0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2024.110240_b0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","article-title":"Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer","volume":"26","author":"Scorsetti","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2024.110240_b0070","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.3390\/curroncol29100621","article-title":"Stereotactic body radiation therapy for lung and liver Oligometastases from breast cancer: toxicity data of a prospective non-randomized phase II trial","volume":"29","author":"Franceschini","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0075","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00066-022-01938-x","article-title":"Oligometastasis in breast cancer\u2014current status and treatment options from a radiation oncology perspective","volume":"198","author":"Piroth","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2024.110240_b0080","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). proc am soc","volume":"40","author":"Chmura","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Chiaojung","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110240_b0090","doi-asserted-by":"crossref","unstructured":"Reddy JP, Liu S, Bathala T et al. Addition of Metastasis-Directed Therapy to Standard of Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase II Trial. International Journal of Radiation Oncology*Biology*Physics Volume 117, Issue 2, Supplement, 1 October 2023, Pages S136-S137.","DOI":"10.1016\/j.ijrobp.2023.06.541"},{"key":"10.1016\/j.radonc.2024.110240_b0095","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2022.06.100","article-title":"Imaging-based prevalence of Oligometastatic disease: a single-center cross-sectional study","volume":"114","author":"Christ","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110240_b0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","article-title":"Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group","volume":"91","author":"deSouza","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2024.110240_b0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","article-title":"Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade","volume":"131","author":"Milano","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0110","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast can cer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110240_b0115","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1002\/cam4.4068","article-title":"Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer","volume":"10","author":"Wijetunga","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2024.110240_b0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12282-023-01436-7","article-title":"Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)","volume":"30","author":"Imoto","year":"2023","journal-title":"Breast Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:38:51Z","timestamp":1741455531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024001622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"alternative-id":["S0167814024001622"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110240","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110240"}}